Novacyt : Results of AGM per resolution

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Result of AGM

The results of the Ordinary General Meeting are set out in the table below, with the Company pleased to announce that all ordinary resolutions proposed to the shareholders were duly passed:

1) Approval of the Company's individual	For	5,065,803	Adopted	87,8432%
financial statements for the year ended 31
Against	701,067
December 2022 (Resolution No. 1),
Abstention	155,203
2) Approval of the Company's consolidated	For	5,065,803	Adopted	87,8432%
financial statements for the year ended 31
Against	701,067
December 2021 (Resolution No. 2),
Abstention	155,203
3) Allocation of the Company's loss for the	For	5,039,278	Adopted	87,1800%
year ended 31 December 2021 (Resolution
Against	741,039
No. 3),
	Abstention	141,756
4)	Authorization of the related parties	For	5, 046,981	Adopted	87,4778%
agreements referred to in Articles L. 225-38
Against	722,464
et	seq. of the French	Commercial Code
Abstention	152,628
(Resolution No. 4),
5)	Discharge to the	Board of Directors	For	3,946,733	Adopted	67,6976%
(Resolution No. 5),
	Against	1,883,213
			Abstention	92,127
6) Authorisation for the Company to buy	For	4,114,970	Adopted	69,9598%
back its own shares (Resolution No. 6),
Against	1,766,940
			Abstention	40,163
7) Ratification of the appointment of a	For	4,611,646	Adopted	79,5069%
non-voting member (censeur) of the Board
Against	1,188,665
of Directors (Resolution No. 7),
Abstention	121,762
8) Ratification of the appointment of a	For	4,819,353	Adopted	82,9845%
non-voting member (censeur) of the Board
Against	988,178
of Directors (Resolution No. 8),
Abstention	114,542
9) Appointment of a member of the Board	For	4,546,913	Adopted	78,1769%
of Directors (Resolution No. 9),
Against	1,269,269
			Abstention	105,891
10) Appointment of a member of the Board	For	4,839,961	Adopted	83,2870%
of Directors (Resolution No. 10),
Against	971,221
			Abstention	110,891
11) Reappointment of a board member	For	4,614,828	Adopted	79,8748%
(Resolution No. 11),
	Against	1,162,751
			Abstention	144,494
12) Reappointment of a board member	For	4,692,570	Adopted	81,2944%
(Resolution No. 12),
	Against	1,079,747
			Abstention	149,756
13) Powers for formalities (Resolution	For	4,993,420	Adopted	85,1472%
No. 13),
	Against	871,033
			Abstention	57,620

Number of participating shareholders (by voting form, electronic vote, proxy or present): 639 shareholders representing 5,922,073 shares.

Contacts
Novacyt SA	[phone]
James Wakefield, Non-Executive Chairman
James McCarthy, Acting Chief Executive Officer
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)	[phone]
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Deutsche Numis (Joint Broker)	[phone]
Freddie Barnfield / Duncan Monteith / Michael Palser
Allegra Finance (French Listing Sponsor)	[phone]
Rémi Durgetto / Yannick Petit	[e-mail]/
	[e-mail]
Walbrook PR (Financial PR & IR)	[phone]
Stephanie Cuthbert / Anna Dunphy / Phillip Marriage	[e-mail]

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

The acquisition of Yourgene in September 2023 added a complementary international genomics technology and services business, focussed on delivering accurate molecular diagnostic and screening solutions, across reproductive health and precision medicine. Yourgene's portfolio of in vitro diagnostic products includes non- invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also works in partnership with global leaders in DNA technology to allow its Ranger® Technology to deliver dynamic target enrichment.

Novacyt is headquartered in Vélizy in France with offices in the UK in Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei (divestment pending), Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com